A pilot study of topotecan in the treatment of serous carcinoma of the uterus

Joseph T. Chambers, T. J. Rutherford, P. E. Schwartz, M. L. Carcangiu, Setsuko K Chambers, L. Baker

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A pilot study investigated topotecan (Hycamtin, GlaxoSmithKline, Philadelphia, PA), a topoisomerase I inhibitor, in treating uterine serous carcinoma, a typically unresponsive aggressive tumor. Fifteen patients were surgically staged, then treated with topotecan (1.5 mg/m2, Days 1-5 every 21 days) as first-line therapy (n = 12) or secondary to platinum failure (n = 3). Patients received topotecan through six courses, disease progression, or unacceptable toxicity. Grade 3/4 hematologic toxicity prompted dose adjustments. Thirteen patients exhibited no gross evidence of residual disease postoperatively. At topotecan initiation, one patient had 5-cm and one had < 1-cm residual disease. Seventy-eight courses (median, six) were administered; 12 (80%) patients completed the specified protocol. Common serious toxicities included grade 3 neutropenia (33%), anemia (13%), and thrombocytopenia (13%). Eight patients received erythropoietin and/or granulocyte colony-stimulating factor. Median follow-up for 14 evaluable patients was 26 months (range, 13-40). Of 11 evaluable first-line topotecan patients, nine were alive at follow-up; five were disease-free. Of three second-line topotecan patients, two died and one was alive with disease 31 months post-treatment. One patient with measurable disease achieved a complete and one a partial response as assessed by computed tomography scan. Median progression-free survival was 25 months; median survival has not been reached at 26 months. Although topotecan's antitumor activity cannot yet be quantified, disease-free interval and survival outcomes compare favorably with other therapies in uterine serous carcinoma. Further evaluation of topotecan in this population is warranted.

Original languageEnglish (US)
Pages (from-to)216-222
Number of pages7
JournalInternational Journal of Gynecological Cancer
Volume13
Issue number2
DOIs
StatePublished - Mar 2003
Externally publishedYes

Fingerprint

Topotecan
Uterus
Carcinoma
Therapeutics
Disease-Free Survival
Topoisomerase I Inhibitors
Granulocyte Colony-Stimulating Factor
Erythropoietin
Neutropenia
Platinum
Thrombocytopenia
Disease Progression
Anemia
Tomography

Keywords

  • Hycamtin
  • Myelosuppression
  • Topoisomerase I inhibitor
  • Topotecan
  • Uterine serous carcinoma

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Cancer Research

Cite this

A pilot study of topotecan in the treatment of serous carcinoma of the uterus. / Chambers, Joseph T.; Rutherford, T. J.; Schwartz, P. E.; Carcangiu, M. L.; Chambers, Setsuko K; Baker, L.

In: International Journal of Gynecological Cancer, Vol. 13, No. 2, 03.2003, p. 216-222.

Research output: Contribution to journalArticle

Chambers, Joseph T. ; Rutherford, T. J. ; Schwartz, P. E. ; Carcangiu, M. L. ; Chambers, Setsuko K ; Baker, L. / A pilot study of topotecan in the treatment of serous carcinoma of the uterus. In: International Journal of Gynecological Cancer. 2003 ; Vol. 13, No. 2. pp. 216-222.
@article{49c362a99c664063a934ce1ef7272842,
title = "A pilot study of topotecan in the treatment of serous carcinoma of the uterus",
abstract = "A pilot study investigated topotecan (Hycamtin, GlaxoSmithKline, Philadelphia, PA), a topoisomerase I inhibitor, in treating uterine serous carcinoma, a typically unresponsive aggressive tumor. Fifteen patients were surgically staged, then treated with topotecan (1.5 mg/m2, Days 1-5 every 21 days) as first-line therapy (n = 12) or secondary to platinum failure (n = 3). Patients received topotecan through six courses, disease progression, or unacceptable toxicity. Grade 3/4 hematologic toxicity prompted dose adjustments. Thirteen patients exhibited no gross evidence of residual disease postoperatively. At topotecan initiation, one patient had 5-cm and one had < 1-cm residual disease. Seventy-eight courses (median, six) were administered; 12 (80{\%}) patients completed the specified protocol. Common serious toxicities included grade 3 neutropenia (33{\%}), anemia (13{\%}), and thrombocytopenia (13{\%}). Eight patients received erythropoietin and/or granulocyte colony-stimulating factor. Median follow-up for 14 evaluable patients was 26 months (range, 13-40). Of 11 evaluable first-line topotecan patients, nine were alive at follow-up; five were disease-free. Of three second-line topotecan patients, two died and one was alive with disease 31 months post-treatment. One patient with measurable disease achieved a complete and one a partial response as assessed by computed tomography scan. Median progression-free survival was 25 months; median survival has not been reached at 26 months. Although topotecan's antitumor activity cannot yet be quantified, disease-free interval and survival outcomes compare favorably with other therapies in uterine serous carcinoma. Further evaluation of topotecan in this population is warranted.",
keywords = "Hycamtin, Myelosuppression, Topoisomerase I inhibitor, Topotecan, Uterine serous carcinoma",
author = "Chambers, {Joseph T.} and Rutherford, {T. J.} and Schwartz, {P. E.} and Carcangiu, {M. L.} and Chambers, {Setsuko K} and L. Baker",
year = "2003",
month = "3",
doi = "10.1046/j.1525-1438.2003.13022.x",
language = "English (US)",
volume = "13",
pages = "216--222",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A pilot study of topotecan in the treatment of serous carcinoma of the uterus

AU - Chambers, Joseph T.

AU - Rutherford, T. J.

AU - Schwartz, P. E.

AU - Carcangiu, M. L.

AU - Chambers, Setsuko K

AU - Baker, L.

PY - 2003/3

Y1 - 2003/3

N2 - A pilot study investigated topotecan (Hycamtin, GlaxoSmithKline, Philadelphia, PA), a topoisomerase I inhibitor, in treating uterine serous carcinoma, a typically unresponsive aggressive tumor. Fifteen patients were surgically staged, then treated with topotecan (1.5 mg/m2, Days 1-5 every 21 days) as first-line therapy (n = 12) or secondary to platinum failure (n = 3). Patients received topotecan through six courses, disease progression, or unacceptable toxicity. Grade 3/4 hematologic toxicity prompted dose adjustments. Thirteen patients exhibited no gross evidence of residual disease postoperatively. At topotecan initiation, one patient had 5-cm and one had < 1-cm residual disease. Seventy-eight courses (median, six) were administered; 12 (80%) patients completed the specified protocol. Common serious toxicities included grade 3 neutropenia (33%), anemia (13%), and thrombocytopenia (13%). Eight patients received erythropoietin and/or granulocyte colony-stimulating factor. Median follow-up for 14 evaluable patients was 26 months (range, 13-40). Of 11 evaluable first-line topotecan patients, nine were alive at follow-up; five were disease-free. Of three second-line topotecan patients, two died and one was alive with disease 31 months post-treatment. One patient with measurable disease achieved a complete and one a partial response as assessed by computed tomography scan. Median progression-free survival was 25 months; median survival has not been reached at 26 months. Although topotecan's antitumor activity cannot yet be quantified, disease-free interval and survival outcomes compare favorably with other therapies in uterine serous carcinoma. Further evaluation of topotecan in this population is warranted.

AB - A pilot study investigated topotecan (Hycamtin, GlaxoSmithKline, Philadelphia, PA), a topoisomerase I inhibitor, in treating uterine serous carcinoma, a typically unresponsive aggressive tumor. Fifteen patients were surgically staged, then treated with topotecan (1.5 mg/m2, Days 1-5 every 21 days) as first-line therapy (n = 12) or secondary to platinum failure (n = 3). Patients received topotecan through six courses, disease progression, or unacceptable toxicity. Grade 3/4 hematologic toxicity prompted dose adjustments. Thirteen patients exhibited no gross evidence of residual disease postoperatively. At topotecan initiation, one patient had 5-cm and one had < 1-cm residual disease. Seventy-eight courses (median, six) were administered; 12 (80%) patients completed the specified protocol. Common serious toxicities included grade 3 neutropenia (33%), anemia (13%), and thrombocytopenia (13%). Eight patients received erythropoietin and/or granulocyte colony-stimulating factor. Median follow-up for 14 evaluable patients was 26 months (range, 13-40). Of 11 evaluable first-line topotecan patients, nine were alive at follow-up; five were disease-free. Of three second-line topotecan patients, two died and one was alive with disease 31 months post-treatment. One patient with measurable disease achieved a complete and one a partial response as assessed by computed tomography scan. Median progression-free survival was 25 months; median survival has not been reached at 26 months. Although topotecan's antitumor activity cannot yet be quantified, disease-free interval and survival outcomes compare favorably with other therapies in uterine serous carcinoma. Further evaluation of topotecan in this population is warranted.

KW - Hycamtin

KW - Myelosuppression

KW - Topoisomerase I inhibitor

KW - Topotecan

KW - Uterine serous carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0038306997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038306997&partnerID=8YFLogxK

U2 - 10.1046/j.1525-1438.2003.13022.x

DO - 10.1046/j.1525-1438.2003.13022.x

M3 - Article

C2 - 12657127

AN - SCOPUS:0038306997

VL - 13

SP - 216

EP - 222

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 2

ER -